Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD, FASCO
0.75 program credits
- Tiffany Traina, MD, FASCO
0.75 program credits
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 program credits
What’s Next for TROP2-Directed ADCs in TNBC?
What’s Next for TROP2-Directed ADCs in TNBC?
MinuteCE®
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD, FASCO
0.75 program credits
- Tiffany Traina, MD, FASCO
0.75 program credits
Applying Clinical Trial Data in mCSPC Care
Applying Clinical Trial Data in mCSPC Care
Project Oncology®
Applying Clinical Trial Data in mCSPC Care
Steve Jackson, PharmD; Jahan Aghalar, MD
- Steve Jackson, PharmD
- Jahan Aghalar, MD
- Ulka Vaishampayan, MD
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
August 20, 2026
02:30 PM - 03:30 PM ET
1.00 credit
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 03, 2026
02:00 PM - 03:00 PM ET
1.00 credit
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH; Robert Coleman, MD, FACOG
1.00 credit
- Susana Campos, MD, MPH
- Robert Coleman, MD, FACOG
- Debra Richardson, MD
1.00 credit
CME/CE In-Person & Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 11, 2026
Houston, Texas
1.00 credit

Medical News

Medical News
Talquetamab And Teclistamab Show Early Signal In Myeloma
07/20/2026
Read more
Medical News
MRI Radiomics Score And ADC Improve HCC Recurrence Prediction
07/20/2026
Read more
Medical News
ARCHER Trial Explores Vaccine Strategy to Prevent ALK Inhibitor Resistance in Advanced NSCLC
07/17/2026
Read more
Medical News
Ramucirumab Plus Docetaxel Shows Phase II Activity in Gastric Cancer
07/14/2026
Read more

CME/CE

Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
MinuteCE®
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
MinuteCE®
Case Consult: First-Line Treatment in Metastatic TNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 program credits
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 program credits
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
CME/CE Virtual Event
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
September 24, 2026
03:30 PM - 04:30 PM ET
1.00 credit
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME/CE
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits

Clinical Practice

Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
0.75 program credits
- Javier Cortes, MD, PhD
0.75 program credits
MinuteCE®
Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
Tiffany Traina, MD, FASCO; Javier Cortes, MD, PhD
0.75 credits 6 episodes
- Tiffany Traina, MD, FASCO
- Javier Cortes, MD, PhD
0.75 credits 6 episodes
Personalizing Long-Term mCSPC Treatment Decisions
Personalizing Long-Term mCSPC Treatment Decisions
Project Oncology®
Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP; Bilal Siddiqui, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bilal Siddiqui, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CE
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits

Programs

Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS; Prithviraj Bose, MD
- Alexandria May, PharmD, BCPS
- Prithviraj Bose, MD
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Project Oncology®
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Alexandria May, PharmD, BCPS; Neil M. Iyengar, MD
- Alexandria May, PharmD, BCPS
- Neil M. Iyengar, MD
Rethinking Frontline Care in HER2- Metastatic Breast Cancer
Rethinking Frontline Care in HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Rethinking Frontline Care in HER2- Metastatic Breast Cancer
Alexandria May, PharmD, BCPS; Tiffany Traina, MD, FASCO
- Alexandria May, PharmD, BCPS
- Tiffany Traina, MD, FASCO
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Project Oncology®
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Jorge Nieva, MD
- Jorge Nieva, MD